Ken Griffin Pulse Biosciences, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$10.83 - $21.83 $22,743 - $45,843	2,100 Added 21.43%	11,900 $208,000
Q2 2024 Aug 14, 2024	SELL	$6.69 - $14.54 $28,098 - $61,068	-4,200 Reduced 30.0%	9,800 $109,000
Q1 2024 May 15, 2024	SELL	$7.8 - $11.02 $92,040 - $130,036	-11,800 Reduced 45.74%	14,000 $121,000
Q4 2023 Feb 14, 2024	BUY	$3.85 - $12.84 $8,085 - $26,964	2,100 Added 8.86%	25,800 $315,000
Q3 2023 Nov 14, 2023	BUY	$4.03 - $8.73 $95,511 - $206,901	23,700 New	23,700 $95,000
Q1 2023 May 15, 2023	BUY	$2.48 - $3.88 $62,248 - $97,388	25,100 Added 121.84%	45,700 $153,000
Q4 2022 Feb 14, 2023	SELL	$1.73 - $2.89 $20,414 - $34,102	-11,800 Reduced 36.42%	20,600 $57,000
Q3 2022 Nov 14, 2022	BUY	$1.23 - $2.3 $16,605 - $31,049	13,500 Added 71.43%	32,400 $75,000

5.41M

139K

84.2K

Ticker PLSE
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 37,125,900
Market Cap $679M
Description
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using it...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.